Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERTPAC-01 verteporfin photodynamic therapy in unresectable pancreatic carcinoma
2006-004097-28Phase 2Completed
- Sponsor
- UCLH
- Start
- Jan 2009
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of verteporfin in pancreatic cancer (PC), sponsored by UCLH. Primary endpoint: Primary endpoint: diameter of tumour necrosis around single fibre. Started Jan 2009; status: completed.
02
Drugs
verteporfin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2006-004097-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004097-28.